←Back to Expert Scholars
Translational Medicine / 转化医学ADC Lineage Targets
Hendrik Poitz
MD
🏢Daiichi Sankyo🌐Germany
Vice President Clinical Development
18
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Hendrik Poitz contributes to global clinical development of Daiichi Sankyo ADCs including HER2 and HER3 directed agents. His work supports lineage informed ADC strategies across breast, lung, and gastric cancers. He focuses on translating platform chemistry into broad clinical applications.
Share:
🧪Research Fields 研究领域
antibody drug conjugates
HER3
trastuzumab deruxtecan
clinical development
lung cancer
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Hendrik Poitz 的研究动态
Follow Hendrik Poitz's research updates
留下邮箱，当我们发布与 Hendrik Poitz（Daiichi Sankyo）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment